Rasagiline

Tizona Therapeutics expanded its Phase Ib trial of TTX-080, targeting HLA-G in biomarker-defined mCRC, adding two randomised arms assessing TTX-080 with cetuximab and FOLFIRI in the second-line setting for MSS, WT RAS, WT BRAF, HER2-negative mCRC patients. Primary endpoint is overall response rate, with secondary endpoints including safety and survival metrics.

The 2024 NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted with the AIM-HI Accelerator Fund, convened top experts across cancer research, biotech entrepreneurship, pharmaceuticals, investment, and patient advocacy at the National Press Club. The event highlighted cutting-edge cancer research advancements, early detection and intervention, AI in diagnostics and personalized treatment strategies, fostering innovative collaborations, and driving breakthrough solutions. Keynotes and panels discussed immunotherapies, biomarkers, personalized approaches, and AI-powered diagnostics. The summit also featured an Innovative Oncology Company Showcase and investor perspectives, culminating in awards and a panel on the future of cancer research.

A clinical trial combining immunotherapy with targeted treatment for BRAF-mutated anaplastic thyroid carcinoma (ATC) extended patient survival to over 43 months, with 50% responding favorably. Non-BRAF mutation ATC patients had shorter median survival, highlighting the importance of pinpointing specific mutations for effective treatment.

Anti-PD-L1 immunotherapy combined with mutation-directed targeted therapy extended overall survival in anaplastic thyroid carcinoma patients, with a median OS of 19 months. BRAFV600E mutation patients had the longest OS at 43.2 months. The study highlights the benefit of immunotherapy and is now standard care for ATC patients with BRAF mutations at MD Anderson.

Combination of anti-PD-L1 immunotherapy and mutation-directed targeted therapy extended overall survival in anaplastic thyroid carcinoma patients, with median OS of 19 months. BRAFV600E mutation cohort had longest OS at 43.2 months, setting a new record for systematic therapy in ATC.

Erasca announces positive Phase 1b SEACRAFT-1 data for naporafenib plus trametinib in NRASm melanoma, supporting ongoing Phase 3 SEACRAFT-2 trial. SEACRAFT-2 aligns with US and European regulatory paths, with Stage 1 randomized data expected in 2025. The company also reports rapid progress in its RAS targeting franchise, with planned IND submissions on track.

The FDA granted namodenoson an orphan drug designation for pancreatic cancer treatment. Namodenoson, a small, orally bioavailable drug, targets A3 adenosine receptors on cancer cells, inducing apoptosis. A phase 2 study is planned to evaluate its safety and clinical activity in advanced pancreatic cancer patients. Preclinical studies showed namodenoson significantly inhibited pancreatic cancer cell growth and modulated signaling pathways.

The FDA granted orphan drug designation to namodenoson for pancreatic cancer treatment. Namodenoson, targeting A3AR on cancer cells, induces apoptosis and is safe due to A3AR's low expression on normal cells. A phase 2 study is planned to evaluate its safety and clinical activity. Preclinical studies showed significant dose-dependent inhibition of pancreatic cancer cell growth and modulation of signaling pathways, supporting further evaluation.

Advances in AML biology reveal new prognostic biomarkers, therapeutic strategies, and CAR-T cell efficacy, focusing on transcriptomic signatures, autophagy, lysosome-related genes, SET-CAN/NUP214 fusion, RAS mutations, and single-cell sequencing.